NASDAQ$JBIO
Jade Biosciences Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced third quarter 2022 financial results.
Aerovate Therapeutics reported a net loss of $13.6 million for the third quarter ended September 30, 2022, compared to a net loss of $6.2 million for the third quarter ended September 30, 2021. Research and development expenses were $10.8 million, and general and administrative expenses were $3.4 million. Cash, cash equivalents, and short-term investments totaled $142.6 million as of September 30, 2022.
- Progress continued for IMPAHCT Global Phase 2b/Phase 3 Clinical Trial.
- IMPAHCT Clinical Trial Design was presented at CHEST.
- Expanded Intellectual Property Portfolio with two additional patents issued in the U.S.
- Sanjeev Khindri joined leadership team as Senior Vice President, Clinical Development.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Forward guidance
Aerovate expects that its cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second half of 2025, based on its current operating plan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro